18/02/2025
Update on Retinitis Pigmentosa
New gene therapy MCO-010 (Multi-Characteristic Opsin Gene) developed by Nanoscope Therapeutics and Dr. Allen Ho, presented findings of phase 2b/3 trial October 2024 at the American Academy of Ophthalmology in Chicago. It is a one time intravitreal injection of a harmless virus, delivering copies of a gene leading to production of light sensing molecules to surviving photoreceptors.
40-50 % of patients responded with improvement of 2-3 lines of vision. It has been submitted to US FDA for fast track approval early this year.
What this means for our Philippine patients? There's a good medicine being developed, but we need to wait re pricing and availability for our country as US regulatory agencies verify these findings. We will update this page as soon as new information becomes available.
Send a message to learn more
